L. Pittarelli

Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

D. Schmatz, R. Schwartz, M. Turner, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Field Test: This activity was field tested for time

M. Glesby, F. Bagnoud, L. Pittarelli, 2015 .

Regression and Clonally Distinct Recurrence of Human Immunodeficiency Virus Related Burkitt-Like Lymphoma During Antiretroviral Therapy

E. Jaffe, M. Raffeld, L. Sorbara, 2001, Leukemia & lymphoma.

Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats

D. Schmatz, J. Anderson, P. Liberator, 1992, Antimicrobial Agents and Chemotherapy.

Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection

D. Schmatz, M. Powles, L. Pittarelli, 1992, Infection and immunity.

Treatment ofPneumocystis carinji pneumonia with1,3-f3-glucan synthesis inhibitors

D. Schmatz, K. Wilson, R. Fromtling, 1990 .

Comparative study of antipneumocystis agents in rats by using a Pneumocystis carinii-specific DNA probe to quantitate infection

D. Schmatz, J. Anderson, M. Becker-Hapak, 1992, Journal of clinical microbiology.

Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.

D. Schmatz, J. Anderson, P. Liberator, 1991, The Journal of protozoology.